| Novartis & Servier | S64315/MIK665 | MCL-1 selective | r/r DLBCL, r/r MM, r/r AML/MDS (combinations with VOB560 (BCL-2 inhibitor) or azacitidine) | IV | I/II | NCT04629443 | Recruiting |
| Amgen | AMG 176 | MCL-1 selective | r/r MM, r/r AML monotherapy or combinations w/ azacitidine or itraconazole | IV | I | NCT02675452 | Recruiting |
| Prelude Therapeutics | PRT1419 | MCL-1 selective | r/r Hematological malignancies, r/r Solid tumors monotherapy or combination with venetoclax | IV/Oral | I | NCT05107856 | Recruiting |
| Gilead | GS-9716 | MCL-1 selective | r/r Solid tumors monotherapy or combinations (multiple) | Oral | Ia/Ib | NCT05006794 | Recruiting |
| Anji Pharmaceuticals | ANJ810 | MCL-1 selective | - | - | Preclin | - | - |
| Captor Therapeutics | CPT-6281 | MCL-1 molecular glue degrader | | - | Preclin | - | - |